Exelixis Inc Increase (Decrease) in Accounts Payable
Exelixis Inc (EXEL) reported Increase (Decrease) in Accounts Payable of -$12.87 million for the 6-month period ending 2026-07-03, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-05
- Exelixis Inc increase (decrease) in accounts payable for the quarter ending 2026-07-03 was $5.03M.
- Exelixis Inc increase (decrease) in accounts payable for the quarter ending 2026-04-03 was -$17.90M, a 310.53% decline year-over-year.
- Exelixis Inc increase (decrease) in accounts payable for the quarter ending 2026-01-02 was -$12.90M, a 675.12% decline year-over-year.
- Exelixis Inc increase (decrease) in accounts payable for the quarter ending 2025-10-03 was $17.75M, a 32.73% decline year-over-year.
- Exelixis Inc increase (decrease) in accounts payable for fiscal 2026 was -$50.15M.
- Exelixis Inc increase (decrease) in accounts payable for fiscal 2025 was -$21.89M, a 143.68% decline from fiscal 2023.
- Exelixis Inc increase (decrease) in accounts payable for fiscal 2023 was $50.11M, a 114.50% increase from fiscal 2022.
- Exelixis Inc increase (decrease) in accounts payable for fiscal 2022 was $23.36M, a 57.60% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 3 month as first filed | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 6 month as first filed | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 9 month as first filed | Increase (Decrease) in Accounts Payable 12 month | Increase (Decrease) in Accounts Payable 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-07-03 | $5.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$12.87M 10-Q · filed 2026-08-05 | -$25.77M derived: sum of 3 quarters · filed 2026-08-05 | -$8.01M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-04-03 | -$17.90M 10-Q · filed 2026-05-05 | -$30.80M derived: sum of 2 quarters · filed 2026-05-05 | -$13.04M derived: sum of 3 quarters · filed 2026-05-05 | -$76.55M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-01-02 | -$12.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $4.86M derived: sum of 2 quarters · filed 2026-02-10 | -$58.65M derived: sum of 3 quarters · filed 2026-08-05 | -$50.15M 10-K · filed 2026-02-10 | ||||
| 2025-10-03 | $17.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$45.75M derived: sum of 2 quarters · filed 2026-08-05 | -$37.25M 10-Q · filed 2025-11-04 | -$35.01M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-07-04 | -$63.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$55.01M 10-Q · filed 2026-08-05 | -$52.76M derived: sum of 3 quarters · filed 2026-08-05 | -$26.37M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-04-04 | $8.50M 10-Q · filed 2026-05-05 | $10.74M derived: sum of 2 quarters · filed 2026-05-05 | $37.14M derived: sum of 3 quarters · filed 2026-05-05 | $20.86M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2025-01-03 | $2.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $28.64M derived: sum of 2 quarters · filed 2026-02-10 | $12.36M derived: sum of 3 quarters · filed 2026-02-10 | -$21.89M 10-K · filed 2026-02-10 | ||||
| 2024-09-27 | $26.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $10.12M derived: sum of 2 quarters · filed 2025-11-04 | -$24.13M 10-Q · filed 2025-11-04 | $19.51M derived: sum of 4 quarters · filed 2026-02-10 | ||||
| 2024-06-28 | -$16.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-28 | -$50.52M 10-Q · filed 2025-07-28 | -$6.88M derived: sum of 3 quarters · filed 2026-02-10 | -$6.15M derived: sum of 4 quarters · filed 2026-02-10 | ||||
| 2024-03-29 | -$34.25M 10-Q · filed 2025-05-13 | $9.39M derived: sum of 2 quarters · filed 2026-02-10 | $10.13M derived: sum of 3 quarters · filed 2026-02-10 | $15.44M derived: sum of 4 quarters · filed 2026-02-10 | ||||
| 2023-12-29 | $43.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $44.37M derived: sum of 2 quarters · filed 2026-02-10 | $49.69M derived: sum of 3 quarters · filed 2026-02-10 | $50.11M 10-K · filed 2026-02-10 | $53.25M 10-K · filed 2024-02-06 | |||
| 2023-09-29 | $737.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | $6.05M derived: sum of 2 quarters · filed 2024-10-29 | $6.47M 10-Q · filed 2024-10-29 | $26.24M derived: sum of 4 quarters · filed 2025-02-11 | ||||
| 2023-06-30 | $5.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $5.73M 10-Q · filed 2024-08-06 | $6.28M 10-Q · filed 2023-08-01 | $25.51M derived: sum of 3 quarters · filed 2025-02-11 | $11.19M derived: sum of 4 quarters · filed 2025-02-11 | |||
| 2023-03-31 | $416.00K 10-Q · filed 2024-04-30 | $1.12M 10-Q · filed 2023-05-09 | $20.19M derived: sum of 2 quarters · filed 2025-02-11 | $5.87M derived: sum of 3 quarters · filed 2025-02-11 | $16.40M derived: sum of 4 quarters · filed 2025-02-11 | |||
| 2022-12-30 | $19.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $5.46M derived: sum of 2 quarters · filed 2025-02-11 | $15.98M derived: sum of 3 quarters · filed 2025-02-11 | $23.36M 10-K · filed 2025-02-11 | $25.84M 10-K · filed 2023-02-07 | |||
| 2022-09-30 | -$14.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | -$3.79M derived: sum of 2 quarters · filed 2023-11-01 | $3.58M 10-Q · filed 2023-11-01 | $6.71M 10-Q · filed 2022-11-01 | $24.81M derived: sum of 4 quarters · filed 2024-02-06 | |||
| 2022-07-01 | $10.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $17.90M 10-Q · filed 2023-08-01 | $39.13M derived: sum of 3 quarters · filed 2024-02-06 | $47.13M derived: sum of 4 quarters · filed 2024-02-06 | ||||
| 2022-04-01 | $7.38M 10-Q · filed 2023-05-09 | $28.60M derived: sum of 2 quarters · filed 2024-02-06 | $36.60M derived: sum of 3 quarters · filed 2024-02-06 | $63.33M derived: sum of 4 quarters · filed 2024-02-06 | ||||
| 2021-12-31 | $21.23M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-06 | $29.23M derived: sum of 2 quarters · filed 2024-02-06 | $55.96M derived: sum of 3 quarters · filed 2024-02-06 | $55.09M 10-K · filed 2024-02-06 | ||||
| 2021-10-01 | $8.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $34.73M derived: sum of 2 quarters · filed 2022-11-01 | $33.87M 10-Q · filed 2022-11-01 | $47.81M 10-Q · filed 2021-11-02 | $33.22M derived: sum of 4 quarters · filed 2023-02-07 | |||
| 2021-07-02 | $26.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $25.86M 10-Q · filed 2022-08-09 | $28.84M 10-Q · filed 2021-08-05 | $25.22M derived: sum of 3 quarters · filed 2023-02-07 | $76.11M derived: sum of 4 quarters · filed 2023-02-07 | |||
| 2021-04-02 | -$867.00K 10-Q · filed 2022-05-10 | $138.00K 10-Q · filed 2021-05-06 | -$1.51M derived: sum of 2 quarters · filed 2023-02-07 | $49.38M derived: sum of 3 quarters · filed 2023-02-07 | $51.77M derived: sum of 4 quarters · filed 2023-02-07 | |||
| 2021-01-01 | -$642.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | $50.25M derived: sum of 2 quarters · filed 2023-02-07 | $52.64M derived: sum of 3 quarters · filed 2023-02-07 | $50.51M 10-K · filed 2023-02-07 | $51.11M 10-K · filed 2021-02-11 | |||
| 2020-10-02 | $50.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $53.28M derived: sum of 2 quarters · filed 2021-11-02 | $51.15M 10-Q · filed 2021-11-02 | $57.47M derived: sum of 4 quarters · filed 2022-02-18 | ||||
| 2020-07-03 | $2.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $262.00K 10-Q · filed 2021-08-05 | $6.58M derived: sum of 3 quarters · filed 2022-02-18 | $25.21M derived: sum of 4 quarters · filed 2022-02-18 | ||||
| 2020-04-03 | -$2.13M 10-Q · filed 2021-05-06 | $4.18M derived: sum of 2 quarters · filed 2022-02-18 | $22.82M derived: sum of 3 quarters · filed 2022-02-18 | $10.04M derived: sum of 4 quarters · filed 2022-02-18 | ||||
| 2020-01-03 | $6.32M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $24.95M derived: sum of 2 quarters · filed 2022-02-18 | $12.17M derived: sum of 3 quarters · filed 2022-02-18 | $39.69M 10-K · filed 2022-02-18 | $44.12M 10-K · filed 2020-02-25 | |||
| 2019-09-27 | $18.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $5.86M derived: sum of 2 quarters · filed 2020-11-05 | $33.37M 10-Q · filed 2020-11-05 | -$2.71M 10-Q · filed 2019-10-30 | $51.76M derived: sum of 4 quarters · filed 2020-11-05 | |||
| 2019-06-28 | -$12.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $14.74M 10-Q · filed 2020-08-06 | $23.00K 10-Q · filed 2019-07-31 | $33.13M derived: sum of 3 quarters · filed 2020-08-06 | $33.41M derived: sum of 4 quarters · filed 2020-08-06 | |||
| 2019-03-29 | $27.52M 10-Q · filed 2020-05-05 | -$1.29M 10-Q · filed 2019-05-01 | $45.91M derived: sum of 2 quarters · filed 2020-05-05 | $46.19M derived: sum of 3 quarters · filed 2020-05-05 | $44.84M derived: sum of 4 quarters · filed 2020-05-05 | |||
| 2018-12-28 | $18.39M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $18.68M derived: sum of 2 quarters · filed 2020-02-25 | $17.33M derived: sum of 3 quarters · filed 2020-02-25 | $17.14M 10-K · filed 2021-02-11 | ||||
| 2018-09-28 | $287.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | -$1.06M derived: sum of 2 quarters · filed 2019-10-30 | -$1.25M 10-Q · filed 2019-10-30 | $25.63M derived: sum of 4 quarters · filed 2020-02-25 | ||||
| 2018-06-29 | -$1.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | -$1.53M 10-Q · filed 2019-07-31 | $25.35M derived: sum of 3 quarters · filed 2020-02-25 | $24.30M derived: sum of 4 quarters · filed 2020-02-25 | ||||
| 2018-03-30 | -$183.00K 10-Q · filed 2019-05-01 | $26.70M derived: sum of 2 quarters · filed 2020-02-25 | $25.65M derived: sum of 3 quarters · filed 2020-02-25 | |||||
| 2017-12-29 | $26.88M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $25.83M derived: sum of 2 quarters · filed 2020-02-25 | $26.30M 10-K · filed 2020-02-25 | $3.01M 10-K · filed 2018-02-26 | ||||
| 2017-09-30 | -$1.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | -$577.00K 10-Q · filed 2017-11-01 | ||||||
| 2017-09-29 | -$1.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $1.34M derived: sum of 2 quarters · filed 2018-11-01 | -$577.00K 10-Q · filed 2018-11-01 | $2.02M derived: sum of 4 quarters · filed 2018-11-01 | ||||
| 2017-06-30 | $2.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $472.00K 10-Q · filed 2017-08-02 | $3.07M derived: sum of 3 quarters · filed 2018-05-02 | $1.60M derived: sum of 4 quarters · filed 2018-05-02 | ||||
| 2017-03-31 | -$1.92M 10-Q · filed 2017-05-01 | $684.00K derived: sum of 2 quarters · filed 2018-05-02 | -$786.00K derived: sum of 3 quarters · filed 2018-05-02 | -$1.01M derived: sum of 4 quarters · filed 2018-05-02 | ||||
| 2016-12-31 | $2.60M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $1.13M derived: sum of 2 quarters · filed 2017-11-01 | $908.00K derived: sum of 3 quarters · filed 2017-11-01 | $164.00K 10-K · filed 2017-02-27 | ||||
| 2016-12-30 | $164.00K 10-K · filed 2019-02-22 | |||||||
| 2016-09-30 | -$1.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | -$1.69M derived: sum of 2 quarters · filed 2017-11-01 | -$2.44M 10-Q · filed 2017-11-01 | |||||
| 2016-06-30 | -$222.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | -$966.00K 10-Q · filed 2017-08-02 | ||||||
| 2016-03-31 | -$744.00K 10-Q · filed 2017-05-01 | |||||||
| 2016-01-01 | -$12.00K 10-K · filed 2018-02-26 | |||||||
| 2015-12-31 | -$12.00K 10-K · filed 2017-02-27 | |||||||
| 2014-12-31 | -$2.93M 10-K · filed 2017-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |